B. Riley Predicts Harrow's Q2 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW - Free Report) - Equities research analysts at B. Riley cut their Q2 2025 earnings per share (EPS) estimates for Harrow in a note issued to investors on Monday, March 31st. B. Riley analyst M. Mamtani now anticipates that the company will earn $0.17 per share for the quarter, down from their previous estimate of $0.25. B. Riley currently has a "Buy" rating and a $65.00 price objective on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow's Q3 2025 earnings at $0.21 EPS and Q4 2025 earnings at $0.38 EPS.

Separately, HC Wainwright restated a "buy" rating and set a $57.00 price target on shares of Harrow in a report on Monday, March 31st.

Harrow Trading Down 2.2 %

NASDAQ HROW traded down $0.54 on Wednesday, hitting $23.52. 520,963 shares of the company were exchanged, compared to its average volume of 504,940. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow has a twelve month low of $9.86 and a twelve month high of $59.23. The firm has a market capitalization of $838.58 million, a P/E ratio of -25.02 and a beta of 0.46. The company's 50 day moving average price is $27.98 and its 200-day moving average price is $37.36.

Harrow (NASDAQ:HROW - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.14. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The company had revenue of $66.83 million for the quarter, compared to analyst estimates of $66.01 million.

Remove Ads

Institutional Investors Weigh In On Harrow

A number of institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its position in shares of Harrow by 443.1% in the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock worth $10,717,000 after purchasing an additional 194,480 shares in the last quarter. Barclays PLC lifted its position in Harrow by 301.9% in the 3rd quarter. Barclays PLC now owns 52,593 shares of the company's stock worth $2,365,000 after buying an additional 39,506 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Harrow by 195.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company's stock valued at $11,313,000 after buying an additional 166,602 shares during the period. State Street Corp boosted its stake in shares of Harrow by 2.2% during the 3rd quarter. State Street Corp now owns 730,973 shares of the company's stock valued at $32,865,000 after buying an additional 15,554 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Harrow during the 3rd quarter valued at $1,469,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.